CLINICAL_TRIALS
trial_result
· 2008-08-06
Clinical Trial Update: Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
Summary
A completed clinical trial investigates fractalkine (CX3CL1) as a mediator of ocular angiogenesis in proliferative diabetic retinopathy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Taiwan University Hospital | Conditions: Proliferative Diabetic Retinopathy, Angiogenesis | Status: COMPLETED